Key Takeaways EW posted Q2 EPS of $0.67 and sales of $1.53B, beating estimates and growing 8.1% and 11.7% YoY, respectively.EW saw strong growth in TAVR and TMTT, driven by U.S. trial data, device adoption and global market shifts.Edwards Lifesciences raised 2025 guidance despite margin pressure from higher costs and expenses.Edwards Lifesciences Corporation (EW) reported second-quarter 2025 adjusted earnings per share (EPS) of 67 cents, which surpassed the Zacks Consensus Estimate by 8.1%. The figure incre ...

Edwards Lifesciences (EW) Q2 2025 Earnings Call July 24, 2025 05:00 PM ET Company ParticipantsMark Wilterding - SVP - IR & Global FinanceBernard Zovighian - CEOScott Ullem - Corporate VP & CFOLarry Wood - Corporate VP, Transcatheter Aortic Valve ReplacementDan Lippis - Corporate Vice PresidentTravis Steed - MD - Equity ResearchDavid Roman - Managing DirectorDaveen Chopra - Corporate Vice President - Transcatheter Mitral & Tricuspid TherapiesMatt Taylor - Managing DirectorAnthony Petrone - MD - Equity Resear ...

Edwards Lifesciences (EW) Q2 2025 Earnings Call July 24, 2025 05:00 PM ET Speaker0Greetings, and welcome to the Edwards Lifesciences Second Quarter twenty twenty five Results Conference Call. At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentation. Please note this conference is being recorded. I will now turn the conference over to your host, Mark Wilterding, Senior Vice President, Global Finance.Thank you. You may begin.Speaker1Thank you ...

Core Viewpoint - Edwards Lifesciences Corp. is set to report its second-quarter 2025 results on July 24, with expectations of revenue and earnings declines compared to the previous year [1][2]. Q2 Estimates - The Zacks Consensus Estimate for revenues is $1.49 billion, indicating an 8.9% decline from the prior year's figure [2]. - The estimate for net earnings is 62 cents per share, reflecting an 11.4% decrease from the year-ago reported figure [2]. Estimate Revision Trend - Earnings estimates have remained unchanged at 62 cents per share over the past 60 days, indicating stability in expectations ahead of the earnings announcement [3]. Factors at Play - The Transcatheter Aortic Valve Replacement (TAVR) segment is expected to perform well in the U.S. due to the SAPIEN 3 Ultra RESILIA platform, with a projected revenue of $1.09 billion, representing a 5.2% year-over-year increase [4][5]. - The TMTT segment is anticipated to show significant growth, with revenues estimated at $130.4 million, a 57.1% improvement from the previous year, driven by the PASCAL and EVOQUE systems [6][8]. Segment Performance - The Surgical Structural Heart segment is expected to report revenues of $263.1 million, suggesting a modest 6.2% rise from the year-ago quarter, supported by the global adoption of the RESILIA portfolio [10][11]. - The commercial launch of the EVOQUE tricuspid replacement system is likely to have progressed well, aided by Medicare coverage [7]. Earnings Whispers - Edwards has an Earnings ESP of 0.00%, indicating no advantage in beating estimates this quarter [12]. - The company currently holds a Zacks Rank of 2 (Buy), suggesting a favorable outlook compared to other stocks [13].

Key Takeaways EW sees strong global uptake in surgical tech and TAVR, with Q1 TAVR sales topping $1 billion again. Edwards' TMTT sales rose 58% in Q1, driven by PASCAL and EVOQUE system adoption across the U.S. and Europe. Macro volatility and foreign exchange headwinds are pressuring EW's operating margin and sales growth.Edwards Lifesciences (EW) is gaining from the robust uptake of its premium surgical technologies. The company’s Transcatheter Aortic Valve Replacement (“TAVR”) platform is positioned fo ...

TIOBE 2025 年 07 月份的编程语言排行榜已经公布， 官 方的 标 题是 ： 主流编程语言竞逐十强席位 ！ （ Senior programming languages battling for a top 10 position ? ） TIOBE最新榜单揭晓 ， Python、C、C++、Java、C#、JavaScript、Go 七大语言连续三年稳居前七，形成牢不可破的"第一阵营"。 而排名经常变化的其实在 第 8 至 12 名 —— Visual Basic、SQL、Fortran、Ada、Perl、Delphi 这个几个语言 展开月度排位拉锯战，上演编程 界的"诸神黄昏"。 Visual Basic、SQL、Fortran、Ada、Perl、Delphi……这些老古董语言可能在简历里已经删了，但它们还在为"前十"的门票拼命竞争。 今天 VB 上来了，明天 Delphi 又冲了个高峰，Fortran 和 Perl 像打不死的小强，不服老也不服输。 按理说，Rust 安全、Kotlin 靓丽，Dart 也有 Flutter 加持，Julia 更是数据科学界的新宠，但现实却是——它们仍然没能挤进 ...

Core Insights - Boston Scientific (BSX) has raised its full-year 2025 guidance for net sales growth to approximately 15-17% on a reported basis and nearly 12-14% on an organic basis, reflecting strong first-quarter results and ongoing momentum in key growth areas [1][8] - The company reported an organic sales growth of 18% in the first quarter, exceeding the guided range of 14-16%, with adjusted EPS at $0.75, a 34% year-over-year increase [2] - The Cardiology segment saw a significant sales increase of 31%, driven by products like WATCHMAN and AGENT drug-coated balloon, while the Electrophysiology business experienced a remarkable 145% year-over-year growth [3][8] Financial Performance - Full-year adjusted earnings per share are now expected to be in the range of $2.87-$2.94, up from the previous estimate of $2.80-$2.87 [1] - The company anticipates a $200 million tariff impact in 2025, primarily in the second half, but plans to offset this through organic sales growth and discretionary spending reductions [4] Competitive Landscape - Competitors like Edwards Lifesciences and Stryker have also adjusted their sales forecasts, with Edwards maintaining an 8-10% growth forecast and Stryker raising its guidance to 8.5-9.5% organic growth [5][6] - Boston Scientific's stock has outperformed the industry, gaining 33.4% over the past year compared to the industry's 8.8% growth [7] Valuation Metrics - Boston Scientific currently trades at a forward 12-month price-to-earnings ratio of 33.19X, which is above the industry average of 20.83X [9]

西北医院明尼阿波利斯心脏研究所瓣膜和结构性心脏病中心主任 Paul Sorajj a 表示： " MAC 会使二尖 瓣的结构变硬而导致二尖瓣反流或狭窄，从而破坏心脏有效泵血的能力，导致患者出现胸痛、呼吸急促和 头晕等症状。此外， 由于MAC患者常伴有多种合并症或其他问题，行心脏直视手术的风险高。 Tendyne 弥合了这些患者的关键治疗差距，并可以帮助减轻可能干扰他们生活的症状。" 思宇年度活动回顾： 首届全球眼科大会 | 首届全球骨科大会 | 首届全球心血管大会 即将召开： 2025年6月12日，首届全球医美科技大会 2025年7月17日，第二届全球医疗科技大会 2025年9月4-5日，第三届全球手术机器人大会 心未来 2025年5月27日， 雅培 宣布其 Tendyne 经导管二尖瓣置换系统 （TMVR） 系统获批FDA，专用于治疗 因严重二尖瓣环钙化（MAC）导致瓣膜功能异常且不适合接受开胸手术 的患者。 # 二尖瓣环钙化（ MAC ） 二尖瓣环钙化 （ Mitral annulus calcification ， MAC ）是二尖瓣纤维支撑结构的一种慢性退行性过 程，主要累及 后瓣环 ，严重病例可形成 ...

IRIDEX (IRIX) Q1 2025 Earnings Call May 13, 2025 05:00 PM ET Company Participants Philip Taylor - PrincipalPatrick Mercer - CEO, President & DirectorRomeo Dizon - CFO Operator Ladies and gentlemen, thank you for standing by. My name is Desiree, and I will be your conference operator today. At this time, I would like to welcome everyone to the First Quarter twenty twenty five IRIDEX Earnings Conference Call. All lines have been placed on mute to prevent any background noise. Thank you. I would now like to tu ...

IRIDEX (IRIX) Q1 2025 Earnings Call May 13, 2025 05:00 PM ET Speaker0 Ladies and gentlemen, thank you for standing by. My name is Desiree, and I will be your conference operator today. At this time, I would like to welcome everyone to the First Quarter twenty twenty five IRIDEX Earnings Conference Call. All lines have been placed on mute to prevent any background noise. Thank you. I would now like to turn the conference over to Trip Taylor of Investor Relations. You may begin. Speaker1 Thank you, and thank ...